Skip to main content
RCEL
NASDAQ Industrial Applications And Services

AVITA Medical Reports Strong Q2, Raises 2026 Revenue Guidance, and Targets Q4 Cash Flow Breakeven

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$5.4
Mkt Cap
$146.189M
52W Low
$3.22
52W High
$7.12
52W Position info
68% above low
Off High info
24% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

RCEL sits 68% above its 52-week low of $3.22.

Summary

AVITA Medical reported strong second-quarter results with significant revenue growth and reduced net loss, raising its full-year 2026 revenue guidance and projecting cash flow breakeven by Q4 2026, directly addressing prior liquidity concerns.


Key Events · Earnings and Guidance · RCEL

  • Strong Q2 Financial Performance

    Net revenue grew 18% year-over-year and 13% sequentially to a record $21.7 million, with gross profit margin increasing to 81.9%.

  • Improved Cash Burn & Breakeven Outlook

    Net cash use significantly improved to $3.2 million from $9.9 million in Q1 2026, with the company now expecting to reach cash flow breakeven in Q4 2026.

  • Raised Full-Year Revenue Guidance

    Full-year 2026 net revenue guidance was increased to a range of $86 million to $89 million, up from the previous $80 million to $85 million.

  • Positive CMS Reimbursement Update

    The Centers for Medicare & Medicaid Services proposed national physician payment for RECELL in 2027, along with increased hospital outpatient and ambulatory surgical center facility payment rates.


Analysis · RCEL · Industrial Applications And Services

This filing is highly important as AVITA Medical has delivered strong Q2 financial results, significantly improving its operational performance and financial outlook. The company's ability to raise full-year revenue guidance and project cash flow breakeven by Q4 2026 directly addresses the "going concern" warning issued in the prior quarter's 10-Q. This indicates a substantial improvement in the company's financial stability and operational execution, reducing near-term liquidity risks and potentially altering the investment thesis.

At the time of this filing, RCEL was trading at $5.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $146.2M. The 52-week trading range was $3.22 to $7.12. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RCEL - Latest Insights

RCEL
Jun 05, 2026, 7:25 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.34
Real-time Price: $5.41 info
Change: +$1.07 (+25%) info
Market Cap: $146.189M info
RCEL
Jun 05, 2026, 7:24 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $4.34
Real-time Price: $5.41 info
Change: +$1.07 (+25%) info
Market Cap: $146.189M info
RCEL
Jun 03, 2026, 7:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.02
Real-time Price: $5.41 info
Change: +$1.39 (+35%) info
Market Cap: $146.189M info
RCEL
May 14, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.67
Real-time Price: $5.41 info
Change: +$0.7426 (+16%) info
Market Cap: $146.189M info
RCEL
May 14, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.62
Real-time Price: $5.41 info
Change: +$0.795 (+17%) info
Market Cap: $146.189M info